蓝帆医疗: 关于间接控股股东变更暨权益变动的提示性公告

Core Viewpoint - The equity change involves Shandong Langhui Petrochemical Co., Ltd. acquiring a 52.0395% stake in Zibo Lanfan Investment Co., Ltd., resulting in a dilution of Lanfan Group's stake from 98% to 47.0013%, changing the indirect controlling shareholder of the company from Lanfan Group to Langhui Petrochemical [1][2][6] Summary by Sections Equity Change Details - Langhui Petrochemical's investment leads to a significant change in ownership structure, with Lanfan Group's stake in Lanfan Investment diluted to 47.0013% [2][4] - The actual controller of the company remains Mr. Li Zhenping, and the number of shares held by Lanfan Investment does not change [1][2] Impact on Company Operations - The equity change does not involve a change in control, nor does it affect the company's business structure, main operations, or financial status adversely [2][6] - There are no implications for the independence of personnel, finances, or asset integrity, and no harm to the interests of the company or minority shareholders is noted [2][6] Financial and Legal Aspects - The capital increase for Lanfan Investment is from RMB 89,600 million to RMB 186,820.4058 million, with the new capital contributed by Langhui Petrochemical through debt-to-equity conversion [5] - The agreement stipulates that any party failing to fulfill their capital contribution obligations will incur a penalty of 0.01% of the unpaid amount per day [5] Shareholding and Pledge Information - As of the announcement date, Lanfan Investment holds 23,478.11 million shares, with 18,330 million shares pledged, representing 18.20% of the total share capital [5][6] - The pledged shares account for 78.07% of the shares directly held by Lanfan Investment and 76.27% of the total shares held by Lanfan Investment and its concerted parties [5]